EGFR and skin squamous cell carcinoma: Adverse events were mainly grade 1, and only 2 cases experienced grade 3 toxicity (acneiform rash).<h4>Conclusion</h4>In a heavily pretreated real-life population with advanced cSCC, the anti-PD1/anti-EGFR combination showed clinical activity with acceptable safety, supporting its role as later-line strategy.